Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease

George F. Atweh, Millicent Sutton, Imad Nassif, Vassiliki Boosalis, George J Dover, Sylvan Wallenstein, Elizabeth Wright, Lillian McMahon, George Stamatoyannopoulos, Douglas V. Faller, Susan P. Perrine

Research output: Contribution to journalArticle

Abstract

High levels of fetal hemoglobin (Hb F) protect from many of the complications of sickle cell disease and lead to improved survival. Butyrate and other short chain fatty acids were previously shown to increase Hb F production in erythroid cells in vitro and in animal models in vivo. However, butyrates are also known to inhibit the proliferation of many cell types, including erythroid cells. Experience with the use of butyrate in animal models and in early clinical trials demonstrated that the Hb F response may be lost after prolonged administration of high doses of butyrate. We hypothesized that this loss of response may be a result of the antiproliferative effects of butyrate. We designed a regimen consisting of intermittent or pulse therapy in which butyrate was administered for 4 days followed by 10 to 24 days with no drug exposure. This pulse regimen induced fetal globin gene expression in 9 of 11 patients. The mean Hb F in this group increased from 7.2% to 21.0% (P <.002) after intermittent butyrate therapy for a mean duration of 29.9 weeks. This was associated with a parallel increase in the number of F cells and F reticulocytes. The total hemoglobin levels also increased from a mean of 7.8 g/dL to a mean of 8.8 g/dL (P <.006). The increased levels of Hb F were sustained in all responders, including 1 patient who has been on pulse butyrate therapy for more than 28 months. This regimen, which resulted in a marked and sustained increase in Hb F levels in more than two thirds of the adult sickle cell patients enrolled in this study, was well tolerated without adverse side effects. These encouraging results require confirmation along with an appropriate evaluation of clinical outcomes in a larger number of patients with sickle cell disease.

Original languageEnglish (US)
Pages (from-to)1790-1797
Number of pages8
JournalBlood
Volume93
Issue number6
StatePublished - Mar 15 1999
Externally publishedYes

Fingerprint

Fetal Hemoglobin
Butyrates
Sickle Cell Anemia
Erythroid Cells
Therapeutics
Animals
Animal Models
Globins
Volatile Fatty Acids
Reticulocytes
Gene expression
Hemoglobins
Cell Count
Cell Proliferation
Clinical Trials
Gene Expression
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Atweh, G. F., Sutton, M., Nassif, I., Boosalis, V., Dover, G. J., Wallenstein, S., ... Perrine, S. P. (1999). Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood, 93(6), 1790-1797.

Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. / Atweh, George F.; Sutton, Millicent; Nassif, Imad; Boosalis, Vassiliki; Dover, George J; Wallenstein, Sylvan; Wright, Elizabeth; McMahon, Lillian; Stamatoyannopoulos, George; Faller, Douglas V.; Perrine, Susan P.

In: Blood, Vol. 93, No. 6, 15.03.1999, p. 1790-1797.

Research output: Contribution to journalArticle

Atweh, GF, Sutton, M, Nassif, I, Boosalis, V, Dover, GJ, Wallenstein, S, Wright, E, McMahon, L, Stamatoyannopoulos, G, Faller, DV & Perrine, SP 1999, 'Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease', Blood, vol. 93, no. 6, pp. 1790-1797.
Atweh GF, Sutton M, Nassif I, Boosalis V, Dover GJ, Wallenstein S et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999 Mar 15;93(6):1790-1797.
Atweh, George F. ; Sutton, Millicent ; Nassif, Imad ; Boosalis, Vassiliki ; Dover, George J ; Wallenstein, Sylvan ; Wright, Elizabeth ; McMahon, Lillian ; Stamatoyannopoulos, George ; Faller, Douglas V. ; Perrine, Susan P. / Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. In: Blood. 1999 ; Vol. 93, No. 6. pp. 1790-1797.
@article{f352890ea4c24d15b72eb5f6ef470993,
title = "Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease",
abstract = "High levels of fetal hemoglobin (Hb F) protect from many of the complications of sickle cell disease and lead to improved survival. Butyrate and other short chain fatty acids were previously shown to increase Hb F production in erythroid cells in vitro and in animal models in vivo. However, butyrates are also known to inhibit the proliferation of many cell types, including erythroid cells. Experience with the use of butyrate in animal models and in early clinical trials demonstrated that the Hb F response may be lost after prolonged administration of high doses of butyrate. We hypothesized that this loss of response may be a result of the antiproliferative effects of butyrate. We designed a regimen consisting of intermittent or pulse therapy in which butyrate was administered for 4 days followed by 10 to 24 days with no drug exposure. This pulse regimen induced fetal globin gene expression in 9 of 11 patients. The mean Hb F in this group increased from 7.2{\%} to 21.0{\%} (P <.002) after intermittent butyrate therapy for a mean duration of 29.9 weeks. This was associated with a parallel increase in the number of F cells and F reticulocytes. The total hemoglobin levels also increased from a mean of 7.8 g/dL to a mean of 8.8 g/dL (P <.006). The increased levels of Hb F were sustained in all responders, including 1 patient who has been on pulse butyrate therapy for more than 28 months. This regimen, which resulted in a marked and sustained increase in Hb F levels in more than two thirds of the adult sickle cell patients enrolled in this study, was well tolerated without adverse side effects. These encouraging results require confirmation along with an appropriate evaluation of clinical outcomes in a larger number of patients with sickle cell disease.",
author = "Atweh, {George F.} and Millicent Sutton and Imad Nassif and Vassiliki Boosalis and Dover, {George J} and Sylvan Wallenstein and Elizabeth Wright and Lillian McMahon and George Stamatoyannopoulos and Faller, {Douglas V.} and Perrine, {Susan P.}",
year = "1999",
month = "3",
day = "15",
language = "English (US)",
volume = "93",
pages = "1790--1797",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease

AU - Atweh, George F.

AU - Sutton, Millicent

AU - Nassif, Imad

AU - Boosalis, Vassiliki

AU - Dover, George J

AU - Wallenstein, Sylvan

AU - Wright, Elizabeth

AU - McMahon, Lillian

AU - Stamatoyannopoulos, George

AU - Faller, Douglas V.

AU - Perrine, Susan P.

PY - 1999/3/15

Y1 - 1999/3/15

N2 - High levels of fetal hemoglobin (Hb F) protect from many of the complications of sickle cell disease and lead to improved survival. Butyrate and other short chain fatty acids were previously shown to increase Hb F production in erythroid cells in vitro and in animal models in vivo. However, butyrates are also known to inhibit the proliferation of many cell types, including erythroid cells. Experience with the use of butyrate in animal models and in early clinical trials demonstrated that the Hb F response may be lost after prolonged administration of high doses of butyrate. We hypothesized that this loss of response may be a result of the antiproliferative effects of butyrate. We designed a regimen consisting of intermittent or pulse therapy in which butyrate was administered for 4 days followed by 10 to 24 days with no drug exposure. This pulse regimen induced fetal globin gene expression in 9 of 11 patients. The mean Hb F in this group increased from 7.2% to 21.0% (P <.002) after intermittent butyrate therapy for a mean duration of 29.9 weeks. This was associated with a parallel increase in the number of F cells and F reticulocytes. The total hemoglobin levels also increased from a mean of 7.8 g/dL to a mean of 8.8 g/dL (P <.006). The increased levels of Hb F were sustained in all responders, including 1 patient who has been on pulse butyrate therapy for more than 28 months. This regimen, which resulted in a marked and sustained increase in Hb F levels in more than two thirds of the adult sickle cell patients enrolled in this study, was well tolerated without adverse side effects. These encouraging results require confirmation along with an appropriate evaluation of clinical outcomes in a larger number of patients with sickle cell disease.

AB - High levels of fetal hemoglobin (Hb F) protect from many of the complications of sickle cell disease and lead to improved survival. Butyrate and other short chain fatty acids were previously shown to increase Hb F production in erythroid cells in vitro and in animal models in vivo. However, butyrates are also known to inhibit the proliferation of many cell types, including erythroid cells. Experience with the use of butyrate in animal models and in early clinical trials demonstrated that the Hb F response may be lost after prolonged administration of high doses of butyrate. We hypothesized that this loss of response may be a result of the antiproliferative effects of butyrate. We designed a regimen consisting of intermittent or pulse therapy in which butyrate was administered for 4 days followed by 10 to 24 days with no drug exposure. This pulse regimen induced fetal globin gene expression in 9 of 11 patients. The mean Hb F in this group increased from 7.2% to 21.0% (P <.002) after intermittent butyrate therapy for a mean duration of 29.9 weeks. This was associated with a parallel increase in the number of F cells and F reticulocytes. The total hemoglobin levels also increased from a mean of 7.8 g/dL to a mean of 8.8 g/dL (P <.006). The increased levels of Hb F were sustained in all responders, including 1 patient who has been on pulse butyrate therapy for more than 28 months. This regimen, which resulted in a marked and sustained increase in Hb F levels in more than two thirds of the adult sickle cell patients enrolled in this study, was well tolerated without adverse side effects. These encouraging results require confirmation along with an appropriate evaluation of clinical outcomes in a larger number of patients with sickle cell disease.

UR - http://www.scopus.com/inward/record.url?scp=0033559320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033559320&partnerID=8YFLogxK

M3 - Article

C2 - 10068649

AN - SCOPUS:0033559320

VL - 93

SP - 1790

EP - 1797

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -